^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    DLL3 expression

    i
    Entrez ID:
    10683
    Related biomarkers:
    Expression
    Apply
    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (NCT04471727)
    Phase 1/2
    Harpoon Therapeutics, Inc., a subsidiary of Mer...
    Recruiting
    Last update posted :
    02/20/2025
    Initiation :
    12/14/2020
    Primary completion :
    06/30/2027
    Completion :
    06/30/2027
    DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (NCT05879978)
    Phase 1/2
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    02/07/2025
    Initiation :
    07/28/2023
    Primary completion :
    09/05/2025
    Completion :
    09/05/2025
    DLL3
    |
    DLL3 expression
    |
    obrixtamig (BI 764532) • ezabenlimab (BI 754091)
    A Study of Peluntamig (PT217) in Patients with Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) (NCT05652686)
    Phase 1/2
    Phanes Therapeutics
    Recruiting
    Last update posted :
    01/31/2025
    Initiation :
    09/05/2023
    Primary completion :
    12/01/2027
    Completion :
    08/01/2028
    EGFR • DLL3
    |
    DLL3 expression
    |
    Tecentriq (atezolizumab) • carboplatin • paclitaxel • etoposide IV • peluntamig (PT217)
    A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3 (NCT05916313)
    Phase 1
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    05/29/2024
    Initiation :
    12/13/2023
    Primary completion :
    08/17/2026
    Completion :
    08/17/2026
    DLL3
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3 (NCT04429087)
    Phase 1
    Boehringer Ingelheim
    Recruiting
    Last update posted :
    04/10/2024
    Initiation :
    07/15/2020
    Primary completion :
    09/02/2024
    Completion :
    09/22/2025
    DLL3
    |
    DLL3 expression
    |
    obrixtamig (BI 764532)
    PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56 (NCT04199741)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    01/11/2024
    Initiation :
    12/11/2019
    Primary completion :
    06/11/2026
    Completion :
    06/11/2026
    DLL3
    |
    DLL3 expression
    Safety, Tolerability and Pharmacokinetics Study of QLS31904 in Patients With Advanced Solid Tumors (QLS31904-101) (NCT05461287)
    Phase 1
    Qilu Pharmaceutical Co., Ltd.
    Recruiting
    Last update posted :
    11/10/2022
    Initiation :
    09/30/2022
    Primary completion :
    09/25/2024
    Completion :
    05/25/2025
    DLL3
    |
    DLL3 expression
    |
    QLS31904
    Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY) (NCT02674568)
    Phase 2
    AbbVie
    Completed
    Last update posted :
    07/30/2021
    Initiation :
    01/25/2016
    Primary completion :
    10/19/2018
    Completion :
    10/19/2018
    DLL3
    |
    DLL3 expression
    |
    Rova-T (rovalpituzumab tesirine)
    Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE) (NCT03061812)
    Phase 3
    AbbVie
    Completed
    Last update posted :
    02/23/2021
    Initiation :
    04/11/2017
    Primary completion :
    02/12/2020
    Completion :
    02/12/2020
    DLL3
    |
    DLL3 expression
    |
    dexamethasone • topotecan • Rova-T (rovalpituzumab tesirine)
    Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer (NCT03334487)
    Phase 3b
    AbbVie
    Withdrawn
    Last update posted :
    12/26/2018
    Initiation :
    03/15/2018
    Primary completion :
    12/20/2018
    Completion :
    12/20/2018
    DLL3
    |
    DLL3 expression
    |
    dexamethasone • Rova-T (rovalpituzumab tesirine)